Long-term cardiometabolic disease risk in women with PCOS by Wekker, V. et al.
Long-term cardiometabolic disease
risk in women with PCOS: a
systematic review and meta-analysis
V. Wekker 1,2,3,4,*, L. van Dammen3,5,6, A. Koning7, K.Y. Heida8,
R.C. Painter1,2, J. Limpens9, J.S.E. Laven10, J.E. Roeters van Lennep11,
T.J. Roseboom1,2,3,4, and A. Hoek5
1Department of Obstetrics and Gynaecology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands 2Amsterdam
Reproduction and Development Research Institute, Amsterdam UMC, Amsterdam, The Netherlands 3Department of Clinical
Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands 4Amsterdam
Public Health Research Institute, Amsterdam UMC, Amsterdam, The Netherlands 5Department of Obstetrics and Gynaecology,
University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands 6Department of Epidemiology, University of
Groningen, University Medical Centre Groningen, Groningen, The Netherlands 7Department of Gynaecology and Obstetrics, Ziekenhuis
Amstelland, Amstelveen, The Netherlands 8Department of Gynaecology and Obstetrics, Wilhelmina Children’s Hospital Birth Centre,
University Medical Centre Utrecht, Utrecht, The Netherlands 9Medical Library, Amsterdam UMC, University of Amsterdam, Amsterdam,
The Netherlands 10Department of Obstetrics and Gynaecology, Erasmus University Medical Centre, Rotterdam, The Netherlands
11Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands
*Correspondence address. Department of Obstetrics and Gynaecology, Amsterdam UMC, University of Amsterdam, Amsterdam, The
Netherlands. E-mail: v.wekker@amsterdamumc.nl https://orcid.org/0000-0002-7143-7299















BACKGROUND: Polycystic ovary syndrome (PCOS) is associated with cardiometabolic disease, but recent systematic reviews and meta-
analyses of longitudinal studies that quantify these associations are lacking.
OBJECTIVE AND RATIONALE: Is PCOS a risk factor for cardiometabolic disease?
SEARCH METHODS: We searched from inception to September 2019 in MEDLINE and EMBASE using controlled terms (e.g. MESH)
and text words for PCOS and cardiometabolic outcomes, including cardiovascular disease (CVD), stroke, myocardial infarction, hyperten-
sion (HT), type 2 diabetes (T2D), metabolic syndrome and dyslipidaemia. Cohort studies and case–control studies comparing the
prevalence of T2D, HT, fatal or non-fatal CVD and/or lipid concentrations of total cholesterol (TC), low-density lipoprotein cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TGs) between women with and without PCOS of 18 years of
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age were eligible for this systematic review and meta-analysis. Studies were eligible regardless of the degree to which they adjusted for con-
founders including obesity. Articles had to be written in English, German or Dutch. Intervention studies, animal studies, conference
abstracts, studies with a follow-up duration less than 3 years and studies with less than 10 PCOS cases were excluded. Study selection,
quality assessment (Newcastle–Ottawa Scale) and data extraction were performed by two independent researchers.
OUTCOMES: Of the 5971 identified records, 23 cohort studies were included in the current systematic review. Women with PCOS had
increased risks of HT (risk ratio (RR): 1.75, 95% CI 1.42 to 2.15), T2D (RR: 3.00, 95% CI 2.56 to 3.51), a higher serum concentration of
TC (mean difference (MD): 7.14 95% CI 1.58 to 12.70 mg/dl), a lower serum concentration of HDL-C (MD: 2.45 95% CI 4.51
to 0.38 mg/dl) and increased risks of non-fatal cerebrovascular disease events (RR: 1.41, 95% CI 1.02 to 1.94) compared to women
without PCOS. No differences were found for LDL-C (MD: 3.32 95% CI 4.11 to 10.75 mg/dl), TG (MD 18.53 95% CI 0.58 to 37.64
mg/dl) or coronary disease events (RR: 1.78, 95% CI 0.99 to 3.23). No meta-analyses could be performed for fatal CVD events due to
the paucity of mortality data.
WIDER IMPLICATIONS: Women with PCOS are at increased risk of cardiometabolic disease. This review quantifies this risk, which
is important for clinicians to inform patients and to take into account in the cardiovascular risk assessment of women with PCOS. Future
clinical trials are needed to assess the ability of cardiometabolic screening and management in women with PCOS to reduce future CVD
morbidity.
Key words: cardiometabolic health / polycystic ovary syndrome / hypertension / type two diabetes mellitus / dyslipidaemia / systematic
review / meta-analysis / long term
Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine
condition in women of reproductive age and has been suggested as a
risk factor for cardiometabolic disease. Depending on which diagnostic
criteria are applied, approximately 6–10% of the women of reproduc-
tive age are affected by PCOS. PCOS is diagnosed based on the pres-
ence of a combination of clinical signs of menstrual irregularities or
anovulation, clinical or biochemical hyperandrogenism and polycystic
ovaries. It is often diagnosed in the reproductive phase of life when
women with PCOS are confronted with infertility, or because of symp-
toms of hyperandrogenism, including acne, alopecia androgenica and
hirsutism (McLuskie and Newth, 2017).
PCOS has been suggested to be a specific female reproductive risk
factor for cardiometabolic diseases such as type 2 diabetes (T2D),
myocardial infarction and stroke, which are the leading causes of death
in women (Dokras, 2013; Harvey et al., 2015). Obesity, one of the
major modifiable risk factors for cardiometabolic disease, frequently
co-occurs with PCOS: approximately half of the women with PCOS
are obese (Figure 1) (Glueck et al., 2005; Rojas et al., 2014).
However, there is no evidence that PCOS is caused by obesity
(Legro, 2012). Both obesity and PCOS are linked to a higher meta-
bolic and cardiovascular disease (CVD) risk, but there is conflicting evi-
dence whether these are independent associations (Moran et al.,
2010; Karabulut et al., 2012). Insulin clamp studies have shown that
women with PCOS also have intrinsic insulin resistance, independent
of weight, suggesting a higher T2D risk, even in the absence of obesity
(Stepto et al., 2013; Cassar et al., 2016).
Current evidence regarding PCOS and cardiometabolic risk is
mostly extracted from cross-sectional studies, comparing cardiometa-
bolic risk factors, such as elevated blood pressure, hyperglycaemia and
dyslipidaemia, between women with and without PCOS, providing in-
formation about associations (Moran et al., 2010; Wild et al., 2011).
The current systematic review and meta-analysis evaluates all evidence
from observational longitudinal studies comparing cardiometabolic risk




This systematic review and meta-analysis is conducted following the
PRISMA guidelines and recommendations of the Cochrane collabora-
tion (Moher et al., 2009; Higgins, 2011). The study protocol was pub-
lished in PROSPERO on 15 July 2015 (Registration number:
PROSPERO 2015 CRD42015023765).
Data sources
A medical information specialist (J.L.) performed a systematic search in
OVID MEDLINE and OVID EMBASE from inception to 2 September
2019, to identify studies that reported the longitudinal association be-
tween PCOS and hypertension (HT), T2D and serum concentrations
of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C),
high-density lipoprotein cholesterol (HDL-C) and triglycerides (TGs),
as well as (non)fatal cardiovascular events (myocardial infarction,
stroke). The search consisted of controlled terms (e.g. MESH) and
text words for PCOS, and cardiometabolic outcomes, including CVD,
stroke, myocardial infarction, HT, T2D, metabolic syndrome and dysli-
pidaemia. The retrieved records were imported in ENDNOTE X7.5
and duplicate records were removed. Cited and citing references of
the included studies were screened for additional relevant publications.
The complete search is presented in Supplementary Data A.
Study selection
Cohort studies and case–control studies comparing the prevalence of
HT, T2D, fatal or non-fatal cardiovascular events and/or lipid concen-
trations (TC, HDL-C, LDL-C and TG) between a group of women
with, and a control group without, PCOS of 18 years of age were el-
igible for this systematic review and meta-analysis. The identification of
PCOS cases could be based on: the National Institutes of Health
(NIH) 1990 (Zawadzki and Dunaif, 1992), androgen excess (AE)-
PCOS (Azziz et al., 2009) and Rotterdam 2003 criteria (Rotterdam
ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004);












































The International Classification of Diseases (ICD)-9/ICD-10 codes,
READ codes; or a combination of at least two of the following symp-
toms: menstrual irregularities or anovulation, hyperandrogenism and
polycystic ovaries. Intervention studies, animal studies, conference
abstracts, studies in languages other than English, German and Dutch,
studies with less than 3 years between PCOS diagnosis and outcome
assessment, and studies with less than 10 PCOS cases were excluded.
Two authors (V.W. and L.v.D.) independently screened all potential
studies on title and abstract with the use of COVIDENCEVR .
Disagreements were solved by discussion. The same authors per-
formed the full-text screening to determine the final selection.
Data extraction and quality assessment
The data extraction and quality assessment was performed by A.K.
and independently cross-checked (by V.W.), using a standardized ex-
traction form (Supplementary Data B). Disagreements were resolved
by discussion and inspection of the original data. The prespecified out-
comes of interest were rates of HT, T2D, (non)fatal CVD events
(myocardial infarction, stroke) and serum concentrations of TC, LDL-
C, HDL-C and TG. To include the data of studies that reported on a
composite outcome of CVD events, including myocardial infarction,
stroke or other vascular events, two additional meta-analyses were
performed. The outcomes could be self-reported, based on medical
records, physical examination or be based on ICD codes. In case of
overlapping outcomes in the same study, population was reported in
multiple publications, the data on the outcome was extracted from
the publication with the longest follow-up duration or largest number
of participants. If data on prespecified outcomes were not reported in
a way that allowed aggregation, corresponding authors were contacted
via institutional e-mail, or the e-mail address published in the article.
The Newcastle–Ottawa Scale for quality assessment of cohort studies
was used for both prospective as retrospective cohort studies (Wells
et al., 2012). This scale assesses the risk of selection bias, the compa-
rability of the groups and ascertainment of exposure and results in a
graphical overview of potential types of bias across the included stud-
ies. A higher number of stars represents a higher study quality.
Summary scores for low (4), moderate (4–7) and high-quality studies
(7) were assigned (Yarmolinsky et al., 2016). However, studies were
not excluded based on the quality assessment.
Statistical analysis
All statistical analyses were performed with Review Manager (RevMan
5.3) (Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2014). Meta-analyses of dichotomous outcomes (HT,
Figure 1. Flow chart of study inclusion for a systematic review and meta-analysis of long-term cardiometabolic disease risk in
women with polycystic ovary syndrome.







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































T2D and CVD events) were performed with the inverse variance
method and a random effects model because the included trials were
expected to differ clinically and methodologically at least to some ex-
tent. The results were reported as risk ratios (RRs) including a 95%
CI. Meta-analyses of continuous outcomes (TC, LDL-C, HDL-C and
TG) were reported as mean differences (MDs) in mg/dl including 95%
CI. If a study compared groups of women with different phenotypes
of PCOS to a control group, then the data of the PCOS groups were
pooled in review manager (Higgins, 2011). Meta-analyses were also
reported in forest plots, including subgroups for study design.
Heterogeneity between studies included in one meta-analysis was eval-
uated using the v2 (significance level: <0.1) and I2 statistic, which
assesses the appropriateness of pooling the individual study results. In
case of considerable heterogeneity (I2 > 70%), sensitivity analyses
were performed excluding studies of which the CI of the study and
summary CI do not overlap (outliers) (Moher et al., 2009; Higgins,
2011). Funnel plot asymmetry was used to detect publication bias if
more than 10 studies were included in one meta-analysis (Higgins,
2011).
Subgroup analyses
All meta-analyses were reported including subgroups for prospective
and retrospective study designs. Sensitivity analyses including high-
quality studies and based on the diagnostic criteria for PCOS (NIH
1990 criteria (Zawadzki and Dunaif, 1992), AE-PCOS criteria (Azziz
et al., 2009) or Rotterdam 2003 criteria (Rotterdam ESHRE/ASRM-
Sponsored PCOS Consensus Workshop Group, 2004)) were per-
formed if three or more studies used the same diagnostic criteria.
Results
Study selection
In the selection process, a total of 23 cohort studies were identified to
be eligible for this systematic review. The 23 studies consist of nine
prospective and 14 retrospective cohort studies, and no case-control
studies. In the prospective cohort studies, a total of 945 women with
PCOS were compared to 5293 women without PCOS. In the retro-
spective cohort studies, a total of 54 894 women with PCOS were
compared to 225 622 women without PCOS. (The study characteris-
tics of the included prospective studies are presented in Table I and of
the retrospective studies in Table II.)
Follow-up duration ranged from approximately 5–31 years.
Fourteen studies were performed in Europe (Cibula et al., 2000; Wild
et al., 2000; Lunde and Tanbo, 2007; Schmidt et al., 2011; Hudecova
et al., 2011a,b, 2010; Morgan et al., 2012; Carmina et al., 2013; Ollila
et al., 2017; Rubin et al., 2017; Glintborg et al., 2018; Meun et al.,
2018; Udesen et al., 2019), six in North America (Talbott et al., 1995;
Lo et al., 2006; Talbott et al., 2007; Wang et al., 2011; Iftikhar et al.,
2012; Merz et al., 2016), two in the Middle East (Ramezani Tehrani
et al., 2015; Kazemi Jaliseh et al., 2017) and one in Oceania (Hart and
Doherty, 2015). The criteria used to diagnose PCOS were the
Rotterdam criteria in seven studies (Schmidt et al., 2011; Hudecova
et al., 2011a,b, 2010; Iftikhar et al., 2012; Carmina et al., 2013;
Udesen et al., 2019), three studies the NIH criteria (Wang et al.,
2011; Ramezani Tehrani et al., 2015; Kazemi Jaliseh et al., 2017), five
studies used ICD codes (Lo et al., 2006; Morgan et al., 2012; Hart and
Doherty, 2015; Rubin et al., 2017; Glintborg et al., 2018) and eight
used a definition based on the presence of either hyperandrogenism,
hirsutism or menstrual irregularities/anovulation (Talbott et al., 1995;
Cibula et al., 2000; Wild et al., 2000; Lunde and Tanbo, 2007; Talbott
et al., 2007; Merz et al., 2016; Ollila et al., 2017; Meun et al., 2018)
(Tables I and II). The risk of bias varied from moderate to high quality
between the studies. On average, the included studies scored seven
out of nine stars. Four studies scored low risk of bias on all eight crite-
ria (nine stars), indicating these studies were of the highest quality
(Table III) (Morgan et al., 2012; Kazemi Jaliseh et al., 2017; Rubin et al.,
2017; Glintborg et al., 2018). The most prevalent high risk of bias was
because of studies not indicating whether the outcome of interest,
such as HT and diabetes, was already present at the start of the
study.
Outcomes
Supplementary Tables SI–SXII show the results according to outcome
and include the definition of the outcome as used in the study, the
number of participants and frequency of the outcomes or, for meta-
bolic outcomes, concentrations in mg/dl. The risk comparisons as
reported by the studies as well as the confounders used in the analysis
for the outcome of interest and factors used to match the populations
are reported in these tables.
Cardiometabolic risk factors
Hypertension. Ten studies (Talbott et al., 1995; Cibula et al., 2000;
Wild et al., 2000; Lo et al., 2006; Lunde and Tanbo, 2007; Schmidt
et al., 2011; Wang et al., 2011; Iftikhar et al., 2012; Hart and Doherty,
2015; Glintborg et al., 2018) were included in the meta-analysis for
HT. Five studies showed a higher rate of HT among women with
PCOS compared to those without PCOS. The meta-analysis showed
a higher rate of HT among women with PCOS compared to women
without PCOS (13.1% vs 6.6%; RR: 1.75, 95% CI 1.42 to 2.15;
I2 ¼ 93%) (Fig. 2a). Subgroup analyses by study design showed no
higher rate in the two prospective studies (RR: 1.35, 95% CI 0.85 to
2.16); I2 ¼ 63%); but a higher rate of HT among women with PCOS
based on the findings of eight retrospective studies (RR: 1.86, 95% CI
1.48 to 2.33; I2 ¼ 94%). Exclusion of three outliers in the meta-
analysis for HT (Lo et al., 2006; Hart and Doherty, 2015; Glintborg
et al., 2018), led to a decrease in the I2 statistic from 94% to 10%, and
a smaller point estimate for HT among women with PCOS compared
to women without PCOS (RR: 1.28, 95% CI 1.11 to 1.48). Visual in-
spection of the funnel plot for the meta-analysis of HT among women
with PCOS compared to women without PCOS did not indicate publi-
cation bias (Fig. 2b). Sensitivity meta-analysis including five high-quality
studies also showed a higher rate of HT among women with PCOS
compared to women without PCOS (12.9% vs 6.3%; RR: 2.07, 95%
CI 1.61 to 2.65; I2 ¼ 95%) (Supplementary Table SXIII).
Type 2 diabetes. Thirteen studies (Cibula et al., 2000; Wild et al., 2000;
Lo et al., 2006; Talbott et al., 2007; Schmidt et al., 2011; Wang et al.,
2011; Hudecova et al., 2011a,b; Iftikhar et al., 2012; Morgan et al.,
2012; Hart and Doherty, 2015; Ollila et al., 2016; Kazemi Jaliseh et al.,
2017; Rubin et al., 2017) were included in the meta-analysis for T2D.
Ten studies reported a higher rate of T2D among women with PCOS




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































compared to those without PCOS. Wild et al. (2000) and Talbott
et al. (2007) reported no higher rate in T2D after adjusting for age
and BMI (Supplementary Table SII). The meta-analysis showed a
higher rate of T2D among women with PCOS compared to women
without PCOS (5.9% vs 2.0%; RR: 3.00, 95% CI 2.56 to 3.51;
I2 ¼ 83%) (Fig. 2c). Subgroup analyses by study design showed a
higher rate of T2D among women with PCOS based on four pro-
spective studies (RR: 2.26, 95% CI 1.74 to 2.94; I2 ¼ 0%) and nine
retrospective studies (RR: 3.29, 95% CI 2.77 to 3.91; I2 ¼ 86%).
Exclusion of two outliers in the meta-analyses for T2D (Lo et al.,
2006; Iftikhar et al., 2012), led to a decrease in the I2 statistic from
83% to 36%, and a smaller point estimate for T2D among women
with PCOS compared to women without PCOS (RR: 3.04, 95% CI
2.77 to 3.35). Visual inspection of the funnel plot for the meta-
analysis of T2D among women with PCOS compared to women
without PCOS did not indicate publication bias (Fig. 2d). Sensitivity
meta-analysis including seven high-quality studies also showed a higher
rate of T2D among women with PCOS compared to women without
PCOS (7.6% vs 2.4%; RR: 3.07, 95% CI 2.48 to 3.80; I2 ¼ 88%)
(Supplementary Table SXIII).
............................................................................................................................................................................................................................






















































































































































































Carmina et al. (2013) P – – * * ** * * */– Moderate
Cibula et al. (2000) R * – * – * * * – Moderate
Glintborg et al. (2018) R * * * * * * * * High
Hart and Doherty (2015) R * * * – ** * * * High
Hudecova et al. (2010) R * * * – ** * * – High
Hudecova et al. (2011a) R * * * * * * * – High
Hudecova et al. (2011b) R * * * – ** * * – High
Iftikhar et al. (2012) R * * * – ** * * * High
Kazemi Jaliseh et al. (2017) P * * * * ** * * * High
Lo et al. (2006) R * * * – ** * – * High
Lunde and Tanbo (2007) R – – * – * * * * Moderate
Merz et al. (2016) P – * – * * * * * Moderate
Meun et al. (2018) P * * * * ** – * * High
Morgan et al. (2012) R * * * * ** * * * Moderate
Ollila et al. (2016) P * * – * ** * * – Moderate
Rubin et al. (2017) R * * * * ** * * * High
Schmidt et al. (2011) P – – – – ** */– * * Moderate
Talbott et al. (1995) R * * * – ** */– * – Moderate
Talbott et al. (2007) R – * * – ** */– * – Moderate
Ramezani Tehrani et al. (2015) P * * * * ** * * – High
Udesen et al. (2019) P * * * * * * * – High
Wang et al. (2011) P * * * – ** * * * High
Wild et al. (2000) R * * – – ** */– * – Moderate
1P, Prospective cohort study; R, Retrospective cohort study; – indicates high risk of bias;
*indicates low risk of bias.
































































































The study of Carmina et al. (2013) compared the lipid concentrations
of 67 women with PCOS who remained anovulatory over time and
30 who became ovulatory separately to a control group without
PCOS (Supplementary Tables SIII–SVI). The pooled mean lipid con-
centrations and SD of the women with PCOS were included in the
meta-analyses.
Total cholesterol. Seven studies (Talbott et al., 1995; Cibula et al., 2000;
Hudecova et al., 2010; Schmidt et al., 2011; Carmina et al., 2013;
Ramezani Tehrani et al., 2015; Udesen et al., 2019) were included in
the meta-analysis for TC concentration (mg/dl). Two studies (Talbott
et al., 1995; Carmina et al., 2013) reported a statistically significantly
higher TC concentration among women with PCOS compared to
those without PCOS (Supplementary Table SIII). The meta-analysis for
TC concentration showed a higher TC concentration among women
with PCOS compared to women without PCOS (MD: 7.14 95% CI
1.58 to 12.70 mg/dl; I2 ¼ 32%) (Fig. 3a). Subgroup analyses by study
design showed no difference in TC concentration based on four pro-
spective studies (MD: 7.27 95% CI 3.43 to 17.97 mg/dl; I2 ¼ 56%),
but a higher TC concentration among women with PCOS based on
three retrospective studies (MD: 7.30 95% CI 1.60 to 13.00 mg/dl; I2
¼ 0%). Subgroup analyses for four studies that diagnosed PCOS using
the Rotterdam 2003 criteria showed no difference in TC concentra-
tion among women with PCOS compared to women without PCOS
(MD: 5.91 95% CI 6.66 to 18.48 mg/dl; I2 ¼ 60%) (Hudecova et al.,
2010; Schmidt et al., 2011; Carmina et al., 2013; Udesen et al., 2019).
Sensitivity meta-analysis including three high-quality studies did not
show a higher TC concentration among women with PCOS (MD:
3.33 95% CI 3.99 to 10.66 mg/dl; I2 ¼ 0%) (Supplementary Table
SXIV).
Low-density lipoprotein cholesterol. Seven studies (Talbott et al., 1995;
Cibula et al., 2000; Hudecova et al., 2010; Schmidt et al., 2011;
Carmina et al., 2013; Ramezani Tehrani et al., 2015; Udesen et al.,
2019) were included in the meta-analysis for LDL-C concentration
(mg/dl). Carmina et al. (2013) reported a statistically significant higher
LDL-C concentration among anovulatory women with PCOS com-
pared to those without PCOS (Supplementary Table SIV). The meta-
analysis for LDL-C concentration showed no difference in LDL-C con-
centration among women with PCOS compared to women without
PCOS (MD: 3.32 95% CI 4.11 to 10.75 mg/dl; I2 ¼ 69%) (Fig. 3b).
Subgroup analyses by study design showed no difference in LDL-C
concentration based on four prospective studies (MD: 4.41 95% CI
7.89 to 16.71 mg/dl; I2 ¼ 79%) and three retrospective studies
(MD: 0.17 95% CI 6.20 to 5.86 mg/dl; I2 ¼ 0%). Subgroup analy-
ses for three studies, which diagnosed PCOS using the Rotterdam
2003 criteria, showed no difference in LDL-C concentration among
women with PCOS compared to women without PCOS (MD: 5.18
95% CI 7.33 to 17.69 mg/dl; I2 ¼ 74%) (Hudecova et al., 2010;
Schmidt et al., 2011; Carmina et al., 2013; Udesen et al., 2019).
Sensitivity meta-analysis including three high-quality studies also
showed no difference in LDL-C concentration (MD: 1.30 95% CI
4.82 to 7.42 mg/dl; I2 ¼ 0%) (Supplementary Table SXIV).
High-density lipoprotein cholesterol. Seven studies (Talbott et al., 1995;
Cibula et al., 2000; Schmidt et al., 2011; Hudecova et al., 2011a,b;
Carmina et al., 2013; Ramezani Tehrani et al., 2015; Udesen et al.,
2019) were included in the meta-analysis for HDL-C concentration
(mg/dl). Two studies (Talbott et al., 2007; Carmina et al., 2013)
reported a statistically significant lower HDL-C concentrations among
women with PCOS compared to those without PCOS
(Supplementary Table SV). The meta-analysis for HDL-C concentra-
tion showed a lower HDL-C concentration among women with
PCOS compared to women without PCOS (MD: 2.45 95% CI
4.51 to 0.38 mg/dl; I2 ¼ 38%) (Fig. 3c). Subgroup analyses by
study design showed no difference in HDL-C concentration based on
four prospective studies (MD: 0.83 95% CI 3.04 to 1.39 mg/dl;
I2 ¼ 15%), but a lower HDL-C concentration based on three retro-
spective studies (MD: 4.58 95% CI 6.96 to 2.20 mg/dl;
I2 ¼ 0%). Subgroup analyses for four studies which diagnosed PCOS
using the Rotterdam 2003 criteria also showed a lower HDL-C con-
centration among women with PCOS compared to women without
PCOS (MD: 2.33 95% CI 4.53 to 0.12 mg/dl; I2 ¼ 0%)
(Hudecova et al., 2010; Schmidt et al., 2011; Carmina et al., 2013;
Udesen et al., 2019). Sensitivity meta-analysis including three high-
quality studies did not show a lower HDL-C concentration among
women with PCOS (MD: 0.47 95% CI 4.41 to 3.48 mg/dl; I2 ¼
30%) (Supplementary Table SXIV).
Triglycerides. Five studies (Talbott et al., 1995; Cibula et al., 2000;
Schmidt et al., 2011; Hudecova et al., 2011a,b; Carmina et al., 2013)
were included in the meta-analysis for TG concentration (mg/dl).
Three studies (Talbott et al., 2007; Schmidt et al., 2011; Hudecova
et al., 2011a,b) reported statistically significant higher TG concentrations
among women with PCOS (Supplementary Table SVI). The meta-analy-
sis for TG concentration showed no difference in TG concentration
among women with PCOS compared to women without PCOS (MD:
18.53 95% CI 0.58 to 37.64 mg/dl; I2 ¼ 79%) (Fig. 3d). Subgroup
analyses by study design showed no difference in TG concentration
based on two prospective studies (MD: 15.02 95% CI 15.91 to 45.95
mg/dl; I2 ¼ 72%) and three retrospective studies (MD: 21.45 95% CI
9.70 to 52.60 mg/dl; I2 ¼ 82%). Subgroup analyses for three studies,
which diagnosed PCOS using the Rotterdam 2003 criteria, showed no
difference in TG concentration among women with PCOS compared
to women without PCOS (MD: 22.15 95% CI 4.00 to 48.30 mg/dl;
I2 ¼ 83%) (Hudecova et al., 2010; Schmidt et al., 2011; Carmina et al.,
2013). Sensitivity meta-analysis based on study quality could not be per-
formed because only one study for this outcome was rated to be of
high quality (Supplementary Table SXIV).
Non-fatal cardiovascular disease events
Coronary events. Seven studies (Cibula et al., 2000; Wild et al., 2000;
Lo et al., 2006; Lunde and Tanbo, 2007; Schmidt et al., 2011; Iftikhar
et al., 2012; Hart and Doherty, 2015) were included in the meta-
analysis for non-fatal coronary events. Hart and Doherty (2015)
reported a statistically significant higher rate of coronary events among
women with PCOS compared to those without PCOS, while adjusting
for obesity. Cibula et al. (2000) reported a higher unadjusted risk
(Supplementary Table SVII). The meta-analysis showed no difference
in non-fatal coronary events among women with PCOS compared to
women without PCOS (0.6% vs 0.35%; RR: 1.78, 95% CI 0.99 to
3.23; I2 ¼ 80%) (Fig. 4a). Subgroup analyses by study design showed
no difference in coronary events based on six retrospective studies
(RR: 1.86, 95% CI 0.97 to 3.55; I2 ¼ 83%). Sensitivity meta-analysis in-
cluding four high-quality studies also showed no difference in non-fatal
coronary events among women with PCOS compared to women







































without PCOS (0.47% vs 0.29%; RR: 1.99, 95% CI 0.83 to 4.80; I2 ¼
89%) (Supplementary Table SXIII).
Cerebrovascular events. Eight studies were included in the meta-analysis
for non-fatal cerebrovascular events (Wild et al., 2000; Lo et al., 2006;
Lunde and Tanbo, 2007; Schmidt et al., 2011; Iftikhar et al., 2012;
Hart and Doherty, 2015; Glintborg et al., 2018; Meun et al., 2018).
Hart and Doherty (2015) and Wild et al. (2000) reported a statistically
significant higher rate of cerebrovascular events in women with PCOS
compared to those without PCOS, while adjusting for measures of
obesity (Supplementary Table SVIII). The meta-analysis showed a
higher rate for cerebrovascular events among women with PCOS
compared to women without PCOS (0.6% vs 0.4%; RR: 1.41, 95% CI
1.02 to 1.94; I2 ¼ 57%) (Fig. 4b). Subgroup analyses by study design
showed no difference in cerebrovascular events based on two pro-
spective studies (RR: 1.11, 95% CI 0.52 to 2.37; I2 ¼ 48%); but a
higher rate in the PCOS group including six retrospective studies (RR:
1.52, 95% CI 1.02 to 2.25; I2 ¼ 64%). Sensitivity meta-analysis includ-
ing six high-quality studies no longer showed a difference in non-fatal
cerebrovascular events among women with PCOS compared to
women without PCOS (0.83% vs 0.54%; RR: 1.27, 95% CI 0.89 to
1.81; I2 ¼ 60%) (Supplementary Table SXIII).
Composite outcomes for non-fatal cardiovascular disease events. Two ret-
rospective studies (Morgan et al., 2012; Glintborg et al., 2018) did not
report separately for coronary or cerebrovascular events
(Supplementary Table SIX) and could therefore not be included in the
meta-analyses for non-fatal coronary and cerebrovascular events.
Glintborg et al. (2018), which was one of these two studies, reported
a higher unadjusted rate of CVD events after excluding women with
HT or dyslipidaemia when they compared women with PCOS to
those without PCOS. Morgan et al. (2012) reported no difference in
large-vessel-disease (myocardial infarction, stroke, angina, central or
peripheral revascularization) based on READ code classifications. The
meta-analysis showed no difference in composite outcome rate for
non-fatal cardiovascular events among women with PCOS compared
to women without PCOS (3.3% vs 2.0%; RR: 1.25, 95% CI 0.92 to
1.69; I2 ¼ 70%) (Fig. 4c). Sensitivity meta-analysis based on study qual-
ity could not be performed because only one study for this outcome
was rated to be of high quality (Supplementary Table SXIII).
Figure 2. Forest plots and funnel plot for meta-analysis of hypertension and type 2 diabetes among women with PCOS com-
pared to women without PCOS. (a) Forest plot for hypertension (HT); (b) Funnel plot for meta-analysis of HT; (c) Forest plot for and type 2 di-
abetes (T2D); (d) Funnel plot for meta-analysis of T2D. The dashed lines in the funnel plots indicate the aggregated point estimate for the
corresponding meta-analysis.
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Figure 3. Forest plot for total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and trigly-
cerides (mg/dl) concentration among women with PCOS compared to women without PCOS. Forest plots for (a) total cholesterol
(TC); (b) low-density lipoprotein cholesterol (LDL-C); (c) high-density lipoprotein cholesterol (HDL-C); (d) triglycerides (TG).
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Figure 4. Forest plot for non-fatal coronary events, non-fatal cerebrovascular events, composite outcome for non-fatal cardio-
vascular disease events and composite outcomes for fatal and non-fatal cardiovascular disease events among women with PCOS
compared to women without PCOS. Forest plots for (a) non-fatal coronary events; (b) non-fatal cerebrovascular events; (c) composite out-
come for non-fatal cardiovascular disease events; (d) composite outcome for fatal cardiovascular disease events.































































































.Fatal cardiovascular disease events
Fatal coronary events. Schmidt et al. (2011) reported on the number of
deaths caused by myocardial infarction in women with PCOS com-
pared to those without PCOS, based on ICD codes. There was no
statistically significant difference in mortality rate between women with
and without PCOS (RR: 14.48, 95% CI 0.14 to 15.83) (Supplementary
Table SX).
Fatal cerebrovascular events. Schmidt et al. (2011) reported on the
number of deaths caused by cerebral haemorrhage in women with
PCOS compared to those without PCOS, based on ICD codes. There
was no statistically significant difference in mortality rate between
women with and without PCOS (RR: 0.58, 95% CI 0.03 to 11.81)
(Supplementary Table SXI).
Composite outcomes for fatal cardiovascular disease events. Two studies
(Iftikhar et al., 2012; Merz et al., 2016) were included in a meta-
analysis on composite outcomes for fatal CVD events. Merz et al.
(2016) included sudden cardiac death, end-stage congestive heart fail-
ure, acute myocardial infarction, peripheral heart disease, and cerebro-
vascular accident in their composite outcome for fatal CVD event.
Iftikhar et al. (2012) included all CVD-related deaths in their composite
outcome for fatal CVD event. Neither study reported a difference in
composite outcome rate for fatal CVD event among women with
PCOS compared to women without PCOS, while adjusting for con-
founders (Supplementary Table SXII). Meta-analysis showed no differ-
ence in composite outcome rate for fatal CVD between women with
PCOS and women without PCOS (2.7% vs 8.0%; RR: 1.30, 95% CI
0.62 to 2.74) (Fig. 4d). Sensitivity meta-analysis based on study quality
could not be performed because only one study for this outcome was
rated to be of high quality (Supplementary Table SXIII).
Discussion
In this systematic review of the literature, based on 23 studies, we
found that women with PCOS were more likely to be diagnosed with
cardiometabolic risk factors, such as T2D and HT, and had a more ad-
verse lipid profile in comparison to women without PCOS. Women
with PCOS also had a higher risk for non-fatal cerebrovascular disease
events but not of coronary disease events. Sensitivity meta-analyses in-
cluding high-quality studies only provided evidence of increased T2D
and HT risks in women with PCOS in comparison to women without
PCOS. The paucity of mortality data did not allow us to draw conclu-
sions concerning fatal outcomes. We were unable to assess the extent
to which increased cardiometabolic risk among women with PCOS
was independent of obesity.
The underlying pathways linking PCOS to T2D, HT, dyslipidaemia
and overt cardiovascular events are complex and involve many inter-
acting cardiovascular and metabolic factors (Meschia et al., 2014).
Intrinsic insulin resistance, often present and linked to hyperandrogen-
ism in women with PCOS, is also associated with cardiometabolic dis-
ease (Ginsberg, 2000; Baptiste et al., 2010; Stepto et al., 2013; Cassar
et al., 2016). Insulin resistance leads to increased lipolysis from adipose
tissue and facilitates dyslipidaemia, which has a toxic effect on the pan-
creatic islet cells (Cerf, 2013). As a result, apoptosis of pancreatic islet
cells is induced, increasing the risk for glucose intolerance and eventu-
ally chronic hyperglycaemia and T2D (Sharma and Alonso, 2014; Oh
et al., 2018). Insulin resistance is also linked to HT through the impair-
ment of the insulin specific endothelial pathway, resulting in vasocon-
striction through a diminished nitrogen oxide production (Muniyappa
et al., 2007). Finally, hyperinsulinaemia leads to vascular inflammation
and water retention in the kidney which contributes to an elevated
blood pressure (Zhou et al., 2014). Dyslipidaemia and elevated blood
pressure are important factors in aggravating the process of athero-
sclerosis eventually leading to cardiovascular events (Tu~nón et al.,
2007).
This systematic review and meta-analysis reports on all important
cardiometabolic outcomes based on longitudinal studies. The search
strategy and systematic methods, including quality assessment, publica-
tion bias assessment, subgroup analyses for study design, sensitivity
analyses and follow-up duration, are among the strengths of this study.
Our study has some limitations, mostly concerning clinical and statisti-
cal heterogeneity. The criteria for PCOS diagnosis were not identical
between studies (Tables I and II), and only for lipids were a sufficient
number of studies using the same diagnostic criteria available to per-
form a subgroup analysis. Therefore, we could not differentiate cardio-
metabolic risk factors and CVD event risks by diagnostic criteria for
PCOS (El Hayek et al., 2016). Furthermore, the diagnostic criteria for
clinical outcomes were heterogeneous between studies. The clinical
heterogeneity between the studies we included might affect the gener-
alizability of our findings to specific clinical settings in which one of the
various diagnostic criteria are used. This is a major limitation of our
study and other studies investigating the relationship between PCOS
and CVD. Considerable heterogeneity (I2 > 70%) was present in the
meta-analyses for non-fatal coronary events, HT, T2D, and TG
(Moher et al., 2009; Higgins, 2011), but exclusion of outliers reduced
the heterogeneity without altering the conclusions (Fletcher, 2007).
For non-fatal coronary events and TG no outliers could be detected,
however step-wise post hoc exclusion of studies of which the CI was
most deviating from the summary CI also reduced the heterogeneity
in the meta-analysis of non-fatal coronary events without consequen-
ces for the conclusion.
Kakoly et al. (2018) showed that risk of T2D in PCOS is increased
by obesity and different in women with PCOS from Europe compared
to Asia, based on meta-regression analyses. However, due to the low
number of included studies per meta-analysis and lack of uniform data
on possible confounding factors such as BMI in the included studies,
we refrained from performing meta-regression analyses (Thompson
and Higgins, 2002). In addition, included studies were performed in
countries with predominantly Caucasian women, therefore we did not
perform subgroup analyses based on ethnicity as described in our pro-
tocol. Consequently, our results are particularly generalizable to the
Caucasian population.
Most of the included studies were of retrospective design and these
studies included the largest number of women. In general, the retro-
spective studies had larger point estimates than the prospective stud-
ies. Although the direction of the overall effect was similar, the meta-
analysis for T2D and HDL-C showed considerate heterogeneity
(I2 > 70%) between the point estimates of the prospective and retro-
spective studies. The heterogeneity is likely to be based on an overes-
timation of the effect in the retrospective studies (Vandenbroucke,
2008). For all other outcomes, the heterogeneity between the sub-
group analyses based on study design was low, indicating that the
overall results of these meta-analyses were independent of study
































































































design (Higgins, 2011). The higher risk estimates for HT and T2D
based on retrospective studies in comparison to the prospective stud-
ies could be explained by ascertainment bias, because women with a
PCOS diagnosis might have had more intensive screening for these
outcomes than women without PCOS.
The follow-up studies included in this meta-analysis corrected for
various confounders including obesity (Tables I and II). This makes it
impossible to study whether the effects are independent of obesity, an
important confounder in the relationship between PCOS and cardio-
metabolic risk (Lim et al., 2012). This question might be better an-
swered by an individual patient data meta-analysis. The eligible studies
were, however, performed many years back, which may present a
barrier to retrieving the data (Tierney et al., 2015). The publication of
anonymized datasets and standardized registration of the PCOS phe-
notype (presence of clinical or biochemical hyperandrogenism; men-
strual irregularities or polycystic ovaries on ultrasonography) and
obesity among studies would allow us to investigate which women di-
agnosed with PCOS have an increased cardiometabolic risk indepen-
dent of obesity (Jovanovic et al., 2010; Bil et al., 2016). The
development of a core outcome set for PCOS, which is currently un-
derway, may help achieve this goal (http://www.comet-initiative.org/
studies/details/1115).
Based on the current unadjusted meta-analyses, the magnitude of
the risk increase in PCOS is comparable to having a first degree family
history of T2D (hazard ratio: 2.72, 95% CI 2.48 to 2.99) (Scott et al.,
2013). PCOS is a stronger risk factor for stroke than a family history
of CVD (odds ratio: 1.38, 95% CI 1.01 to 1.88) (Valerio et al., 2016).
Given the increase in cardiometabolic risk, it is understandable that
cardiometabolic screening of women with PCOS is regularly suggested
in international guidelines (Huang and Coviello, 2012; Andersen and
Glintborg, 2018). However, it is important to consider that increased
risk alone does not justify screening (Andermann et al., 2008).
Screening should only be performed if it leads to earlier recognition of
modifiable cardiometabolic risk factors and if treatment leads to better
health outcomes (Andermann et al., 2008). PCOS is often diagnosed
in young women who have a low absolute risk of overt cardiometa-
bolic disease. Screening for CVD in a relatively low-risk population
may be associated with low yield of preventable cases, considerable
costs and possible harms incurred by overdiagnosis (Lipitz-Snyderman
and Bach, 2013). A randomized trial comparing screening of estab-
lished cardiometabolic risk factors, such as HT, T2D and dyslipidaemia,
in women with PCOS to no screening, in combination with long-term
follow-up to evaluate the effect of treatment on cardiometabolic out-
comes (blood pressure, glucose metabolism and lipids) and event rates
(fatal and non-fatal coronary or cerebrovascular events) to usual care,
would provide the best answer as to whether screening is effective
(Bell et al., 2015). However, these screening studies are non-existent
and are unlikely to be performed in the near future, since they take
decades to perform, due to the time between the diagnosis of PCOS
and CVD events. Despite the absence of compelling evidence in sup-
port of the effectiveness of CVD risk screening in PCOS, the newest
international guideline on PCOS management advises such screening in
all women with PCOS irrespective of BMI (Wild et al., 2010; Teede
et al., 2018). The guideline advises annual blood pressure evaluation
and glycaemic status evaluation every 1–3 years in all women with
PCOS (Teede et al., 2018). However, if the added cardiometabolic
risk of PCOS on top of traditional risk factors is small or if patients
with PCOS who are at risk for cardiometabolic disease already qualify
for screening because of their obesity status, it is unlikely to be cost-
effective to screen all women with PCOS. We suggest a high-quality
longitudinal study in PCOS women stratified for obesity status, prior
to universal screening of all women with PCOS, including those who
are lean (Andermann et al., 2008). Furthermore, early consequences
of PCOS, such as menstrual cycle disturbances and infertility, could be
used as a window of opportunity to prevent long-term cardiometa-
bolic consequences by increasing awareness about the importance of a
healthy lifestyle, and providing support to optimize modifiable lifestyle
factors such as smoking and obesity (Piepoli et al., 2016; van Dammen
et al., 2018).
In conclusion, we found that women with PCOS have a substantially
increased crude risk for future HT and T2D. Also, PCOS might lead
to adverse lipid serum concentrations and increase in non-fatal cere-
brovascular events, although sensitivity meta-analyses including only
high-quality studies did not indicate these associations. We were un-
able to establish point estimates that accounts for excess obesity rates
among women with PCOS. Whether screening strategies can amend
this cardiometabolic risk should be investigated.
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online.
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Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, Mejı́as J, Calvo M,
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